Nav: Home

Industry and academic researchers advance human health at innovative cancer research symposium

March 03, 2016

Summit, NJ (March 3, 2016) - Today, the Damon Runyon Cancer Research Foundation held the fifth annual Accelerating Cancer Cures Research Symposium. The yearly meeting is designed to encourage collaboration between cancer researchers in industry and their counterparts in academia in order to overcome many of the issues that currently impede progress against cancer. Hosted by Celgene, the meeting included academic researchers from top universities and research institutions as well as scientists from Celgene, Eli Lilly and Company, Genentech, Merck, Pfizer, and Takeda Pharmaceuticals International Co.

Accelerating Cancer Cures is a unique collaboration between Damon Runyon, a prestigious cancer charity that supports pioneering early career cancer researchers, and leading biopharmaceutical companies. The goal of this multi-million dollar initiative is to rebuild the ranks of specially trained physician-scientists who conduct both the innovative laboratory research necessary to identify new therapeutics and the clinical trials to bring these new treatments to patients. By collaborating on this initiative, the companies involved demonstrate their shared commitment to driving the next generation of breakthroughs in cancer prevention, diagnosis and treatment.

Over the past two decades, innovative cancer treatments have helped increase survival rates and improved quality of life, allowing cancer patients to spend more time with family and loved ones.
  • The cancer death rate has fallen by 23% since its peak in 1991, in large part due to innovative cancer medicines.
  • Survival is increasing dramatically for many forms of cancer. The five year survival rate has increased 21% for breast cancer; 50% for prostate cancer; 36% for colon cancer; and 54% for lung cancer since 1975.
  • The five year survival rate for patients with leukemia has nearly tripled since the early 1990s.
  • For children, the five year relative survival rate increased from 58% in the mid?1970s to 83% today due to new and improved treatments.
Richard B. Gaynor, MD, Senior Vice President of Global Development/Medical Affairs for Lilly Oncology, Damon Runyon Board member, and Chair of Accelerating Cancer Cures, opened the meeting by welcoming its attendees and stressing the urgency of collaboration between academia and industry at this crucial moment in cancer research. Chas Bountra, PhD, Chief Scientist (Structural Genomics Consortium), Professor of Translational Medicine (Department of Clinical Medicine), of the University of Oxford, delivered a keynote address about how innovative collaborations can catalyze the process of cancer drug discovery. Participants also heard research presentations from selected Damon Runyon scientists and learned from industry panel discussions on bridging the gap between academia and industry. Lorraine Egan, President and CEO of Damon Runyon, and Robert J. Hugin, Executive Chairman of Celgene Corporation, provided opening remarks.

"With more than 200 forms of cancers, we are encouraged that innovative industry leaders have come together to brainstorm models that will advance the development of new treatments for cancer patients," said Ms. Egan. "Through Accelerating Cancer Cures, we are ensuring that the best young physician-scientists are a part of this program and can continue to be the critical link between the research lab and the patients."

"Celgene is honored to be a part of Accelerating Cancer Cures, which provides the type of collaboration needed to accelerate translational research progress that will result in improved treatment options for cancer patients," said Mr. Hugin. "There are over 3,000 compounds in development for cancer around the world. Of those, about 80 percent have the potential to be first?in?class treatments. With continued support for disruptive science and medical innovation, we foresee accomplishing in cancer what has been achieved against other major public health problems, such as HIV/AIDS, in which scientific advances yielded major gains for patients, healthcare and the economy."

Dr. Gaynor added, "This is an exciting time in cancer research with major discoveries in both genetics and immunology leading to innovative cancer therapies. Today we heard presentations from young investigators who are at the forefront of these discoveries bringing novel insights from the laboratory into the clinic. The efforts of the Damon Runyon Foundation and programs like Accelerating Cancer Cures are helping to make the hope of new cancer therapies a reality."

Scientists from the nation's leading research institutions, including University of California at Berkeley, Fred Hutchinson Cancer Research Center, University of Texas at Austin, Icahn School of Medicine at Mount Sinai, Boston Children's Hospital, Memorial Sloan Kettering Cancer Center, and Stanford University School of Medicine attended the symposium to hear presentations on a diverse range of promising research, from novel immunotherapy approaches against cancer to defining new Achilles' heels for all cancer types, and to brainstorm about creative approaches to speed new treatments to cancer patients.
-end-
About Accelerating Cancer Cures

Accelerating Cancer Cures addresses the critical shortage of clinical researchers working on breakthroughs in cancer treatments and cures. Under the leadership of the Damon Runyon Cancer Research Foundation and with the support of industry and academia, this project fosters the talent desperately needed to accelerate breakthroughs in cancer prevention, diagnosis and treatment.

Accelerating Cancer Cures is supported by some of the world's leading companies including: Eli Lilly and Company, Celgene, Genentech, Merck, Pfizer, and Takeda Pharmaceuticals International Co. For more information, visit https://www.damonrunyon.org/for-scientists/accelerating-cancer-cures.

About the Foundation

To accelerate breakthroughs, the Damon Runyon Cancer Research Foundation provides today's best young scientists with funding to pursue innovative cancer research. The Foundation supports emerging leaders who have great potential to achieve breakthroughs in how we diagnose, treat and prevent cancer. Since its founding in 1946, the Foundation has invested over $300 million and funded more than 3,500 young scientists. 100% of all donations to the Foundation are used to support scientific research. Its administrative and fundraising costs are paid from its Damon Runyon Broadway Tickets Service and endowment. For more information visit http://www.damonrunyon.org.

Damon Runyon Cancer Research Foundation

Related Cancer Articles:

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
More Cancer News and Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...